Recently presented preclinical data show that EA Pharma Co. Ltd.'s EA-3571 is a highly potent dual inhibitor of enteropeptidase and trypsin with luminal action, resulting in potential anti-insulin resistance and fat-burning properties.
The enzyme aminocarboxymuconate semialdehyde decarboxylase (ACMSD) is a regulator of de novo NAD+ synthesis and is reduced in patients with advanced liver disease.
Rectify Pharmaceuticals Inc. has conducted preclinical testing on RTY-694, an oral dual-targeted positive functional modulator for use in the treatment of hepatobiliary disorders.
By comparing the transcriptomic profile of tissue regeneration after induced damage in the small intestine and colon with their transcriptomic landscape in their steady state, researchers have identified a pathway that unlinks tissue regeneration from tumorigenesis.
NLRP3 inflammasome activation, pro-inflammatory cytokine production and pyroptosis are key features of inflammation that contribute to liver fibrosis progression, cirrhosis and end-stage liver failure. Pyroptosis, a lytic form of inflammatory-regulated cell death, is regulated by multiprotein complexes expressed in both parenchymal and nonparenchymal hepatic cells. Researchers from Genfit SA presented preclinical efficacy data on CLM-022, a synthetic pentacyclic triterpenoid derivative designed to target the NLRP3 complex.
An international consortium of thousands of scientists is creating the Human Cell Atlas, a three-dimensional map of all the cells in the body. The goal is to understand all the cells that make up human tissues, organs and systems, which will enable multiple medical applications. This collection of cell maps is openly available for navigation at single-cell resolution, identified through omics analyses that reveal the tridimensional distribution of each cell.
Many studies have linked the presence of specific bacteria to various diseases. But a general overgrowth of gut bacteria can be a symptom of different conditions, including colorectal cancer and inflammatory bowel disease.
Evotec International GmbH has disclosed integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.
As a consequence of chronic liver disease progression, severe cirrhosis, decompensation and fibrosis culminates in end-stage liver disease (ESLD). There are no treatment options approved for ESLD, but, among others, regenerative therapies with autologous, nonengineered, pro-regenerative macrophages have shown good tolerability and improved transplant-free survival in the clinical setting.
RSS
